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Objective. Redox imbalance contributes to bone fragility. We have evaluated the in vivo role of nuclear factor erythroid derived
2-related factor-2 (Nrf2), an important regulator of cellular responses to oxidative stress, in bone metabolism using a model
of postmenopausal osteoporosis. Methods. Ovariectomy was performed in both wild-type and mice deficient in Nrf2 (Nrf2−/−).
Bone microarchitecture was analyzed by 𝜇CT. Serum markers of bone metabolism were also measured. Reactive oxygen species
production was determined using dihydrorhodamine 123. Results. Sham-operated or ovariectomized Nrf2−/− mice exhibit a loss
in trabecular bone mineral density in femur, accompanied by a reduction in cortical area in vertebrae. Nrf2 deficiency tended to
increase osteoblastic markers and significantly enhanced osteoclastic markers in sham-operated animals indicating an increased
bone turnover with a main effect on bone resorption. We have also shown an increased production of oxidative stress in bone
marrow-derived cells from sham-operated or ovariectomized Nrf2−/− mice and a higher responsiveness of bone marrow-derived
cells to osteoclastogenic stimuli in vitro. Conclusion. We have demonstrated in vivo a key role of Nrf2 in the maintenance of bone
microarchitecture.
1. Introduction
Multiple pathogenetic mechanisms are responsible for loss
of bone mass and skeletal microarchitectural deterioration
leading to osteoporosis which represents a major challenge
to our health systems. Excessive bone resorption or an inad-
equate bone formation in response to increased resorption
during bone remodeling results in skeletal fragility [1]. Epi-
demiological studies have revealed that the majority of
the affected individuals are postmenopausal women. It is
estimated that in developed countries around 50 percent
of women aged 50 and older will sustain an osteoporotic
fracture during their lifetime. Osteoporotic fractures are
associated with chronic pain and greatly impact the quality of
life. Experimental findings support the concept that estrogen
deficiency leads to increased bone turnover and plays a key
role in osteoporosis [2].
Recent studies have demonstrated an important contribu-
tion of redox imbalance to bone fragility [3] and biochemical
markers of oxidative stress are significantly increased in
osteoporosis [4, 5]. In addition, menopause-related estrogen
withdrawal might contribute to make bone more vulnerable
to oxidative injury. Loss of estrogens decreases defensive
mechanisms against oxidative stress and accelerates the
effects of aging on bone [6]. Therefore, reduced antioxidant
levels would enhance bone resorption [7] whereas the reduc-
tion in oxidative stress may provide protection against oste-
oporosis in aged and ovariectomized rats [8].
Nuclear factor erythroid derived 2-related factor-2 (Nrf2)
plays an important role in the cellular defense against
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oxidative stress by induction of antioxidative and phase-2
detoxifying enzymes. This transcription factor regulates the
expression of bone marrow stromal antioxidants and phase 2
enzymes as well as the susceptibility of these cells to oxidative
and electrophilic stress [9]. In addition, Nrf2 downregu-
lates inflammatory processes [10–12] and innate immune
responses [13, 14]. Loss of Nrf2 leads to an increased sus-
ceptibility to radiation-induced bone loss [15] and recent in
vitro studies have shown a role for this transcription factor
in receptor activator of nuclear factor 𝜅B ligand (RANKL)
induced osteoclastogenesis through modulation of reactive
oxygen species (ROS) signaling [16, 17]. In contrast, some
reports have suggested a negative effect of Nrf2 on bone
mineralization [18, 19]. However, the influence of Nrf2 defi-
ciency on bone metabolism and microstructure in vivo and
the possible role of Nrf2 in osteoporosis are not completely
understood.
Ovariectomized mice may serve as an appropriate model
for type II osteoporosis [20]. Approaches coupling in vitro
observations with events in vivo allow a better understanding
of complex biological interactions and disease mechanisms.
The present study was designed to evaluate the in vivo effects
of Nrf2 deficiency in a model of postmenopausal osteoporo-
sis.
2. Materials and Methods
2.1. Animals and Study Design. All studies were performed
in accordance with European Union regulations for the
handling and use of laboratory animals. The protocols were
approved by the institutional Animal Care and Use Commit-
tee (Comite´ de Etica en Experimentacio´n Animal, University
of Valencia and Autonomous University of Madrid, Spain).
The C57BL/6J Nrf2 knockout mice were kindly provided
by Dr. Masayuki Yamamoto (University of Tsukuba, Japan).
Genotyping of wild-type (Nrf2+/+) C57BL/6J mice and Nrf2-
deficient (Nrf2−/−) littermates was done as reported previ-
ously [22]. Female Nrf2−/− and wild-type C57BL/6J mice
between 6 and 9 months of age were included in this study.
Animals of each strain were randomly allocated to ovar-
iectomy (OVX) (𝑛 = 20) or Sham groups (𝑛 = 20).
Surgery was performed after the mice were anesthetized with
isoflurane and treatedwith butorfanol (2mg/kg, s.c.). Ovaries
of the mice in OVX group were removed through a midline
incision of the skin and flank incisions of the peritoneum.
The skin incision was then closed with metallic clips. Mice
in the sham-operated group were anesthetized and sutured
without removal of the ovaries. All mice were maintained
in cages with a 12-hour light/dark cycle and free access to
standard diet and water. Mice were housed and cared for by
the veterinary staff in accredited facilities and were routinely
screened for health status. On day 30 after surgery, mice
were anesthetized, blood samples were taken by retro-orbital
puncture, and animals were killed by cervical dislocation.
Hind paws and L3–L5 vertebrae from randomly selected
animals in each group were isolated and frozen for 𝜇CT and
histomorphometric analysis.
2.2. Histomorphometric Analysis. Lumbar spines were dis-
sected (L3–L5) and fixed in 10% formalin. After decalci-
fication in 10% EDTA, the specimens were processed for
paraffin embedding. Tissue sections (7 𝜇m)were stained with
hematoxylin and eosin to measure trabecular and cortical
bone area, and osteoblast number relative to bone perimeter
(N.Ob/BPm, mm−1) or with TRAP and counterstained with
hematoxylin and aniline blue to determine the percentage of
bone surface covered by osteoclasts (Oc.S/BS, %).
2.3. Measurement of Bone Markers. Enzyme-linked immu-
noassay (ELISA) kits were used to determine serum lev-
els of tartrate-resistant acid phosphatase (TRAP)-5b, with
sensitivity of 0.1 U/L, and C-terminal telopeptides of type I
collagen (CTX-I), with sensitivity of 2.0 ng/mL (IDS, Paris,
France). Serum levels of osteocalcin, osteoprotegerin (OPG),
and RANKLwere determined by Luminex, with sensitivity of
7.0, 2.3, and 3.3 pg/mL, respectively (Millipore Corporation,
Billerica, MA, USA). Alkaline phosphatase (ALP) levels in
serum were determined as previously described [21].
2.4. X-Ray Microcomputed Tomography (𝜇CT). Hind paws
were kept wrapped in gauzes soaked in 0.9% NaCl at −20∘C
until their analysis by 𝜇CT. Samples were analyzed with a
SkyScan 1172 𝜇CT equipment (Bruker microCTNV, Kontich,
Belgium). Three-dimensional trabecular microarchitecture
was analyzed at the distal metaphysis of the femur in a
region of 1.5mm. Samples were imaged with an X-ray tube
voltage of 50 kV, current of 200𝜇A, at a scanning voxel size
of 5.5𝜇m, and with the use of an aluminum filter (0.5mm in
thickness). The scanning total angular rotation was 185∘ with
an angular increment of 0.4∘. Datasets were reconstructed
using a modified Feldkamp algorithm [23] and segmented
into binary images using adaptive local thresholding previous
to analysis.
2.5. Isolation of Bone Marrow Cells. Bone marrows were
flushed out of femur and tibia with DMEM (Sigma-Aldrich,
St Louis, MO, USA) containing penicillin (100U/mL) and
streptomycin (100mg/mL), supplemented with 10% fetal
bovine serum (Sigma-Aldrich) (complete DMEM) using a
25-gauge needle. Cells were treated with red blood cells lysis
buffer (0.15M NH
4
Cl, 1mM KHCO
3
, 0.1mMNa
2
EDTA, pH
7.4), washed twice with complete DMEM, and seeded in 96-
well tissue culture plates at 5 × 105 cells per well (oxidative
stress quantification) or 3 × 105 cells per well (osteoclast
differentiation).
2.6. Oxidative Stress Quantification. ROS production in bone
marrow-derived cells was determined using dihydrorho-
damine 123 (Molecular Probes, Invitrogen S.A., Barcelona,
Spain), which is oxidized to fluorescent rhodamine 123
(485 nm (excitation)/534 nm (emission)). Cells were washed
with DMEM (Sigma-Aldrich), incubated with dihydrorho-
damine 123 (5 𝜇M) in DMEM for 10min at 37∘C and then
12-O-tetradecanoylphorbol-13 acetate (TPA, 200 ng/mL) was
added and cells were incubated for 30min at 37∘C. Cells were
washed, resuspended in PBS, and analyzed by flow cytometry
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Figure 1: Structure of trabecular bone of femur. (a) Three-dimensional 𝜇CT analysis. vBMD: volumetric bone mineral density; BV/TV:
bone volume fraction; BS/TV: bone surface density; Tb.Sp: trabecular spacing; Tb.N: trabecular number; Tb.Th: trabecular thickness; OVX:
ovariectomy. Results are expressed as mean ± SD (𝑛 = 3). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01. (b) Representative 𝜇CT images of trabecular bone of femur
are shown.
(FACSCanto, Becton Dickinson, Franklin Lake, NJ, USA).
Each experiment was done in triplicate.
2.7. Osteoclast Differentiation. Bone marrow-derived cells
were cultured in complete DMEM medium containing
macrophage-colony stimulating factor (M-CSF) (30 ng/mL)
and RANKL (50 ng/mL). Medium was changed every 2
days. TRAP staining was performed after 8 days of culture.
Cells were fixed with 4% paraformaldehyde in PBS for
5min, washed, and incubated in 0.2M acetate buffer (0.2M
sodium acetate, 0.05M tartaric acid, and water; pH 5.0) for
20min at 37∘C. Cells were then washed and incubated in a
solution containing distilled water, 0.5mg/mL naphthol AS-
MXphosphate (Sigma-Aldrich), and 1.1mg/mL fast red violet
LB salt (Sigma-Aldrich) for 3 h at 37∘C. Finally, cells were
washed and counterstained with hematoxylin/aniline blue,
and TRAP+ multinucleated cells were counted.
2.8. Statistical Analysis. The results are presented as mean ±
SD. The level of statistical significance was determined by
one-way ANOVA followed by Bonferroni’s post test.
3. Results
3.1. Effects on Bone Architecture in Femur. The 𝜇CT analysis
indicated that Nrf2 deficiency in either sham-operated or
ovariectomized mice affected bone architecture in femur. As
shown in Figures 1(a) and 1(b), Nrf2 deficiency significantly
reduced volumetric bone mineral density (vBMD) in trabec-
ular bone and a tendency was observed towards a reduction
in bone volume fraction (BV/TV) and bone surface density
(BS/TV). In addition, Nrf2 deficientmice also tended to show
lower values of trabecular number (Tb.N), accompanied
with a higher trabecular spacing (Tb.Sp) in ovariectomized
mice.
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Figure 2: Bone histomorphometric analysis in lumbar vertebrae. The relative surface of trabecular bone (trabecular/total area) and cortical
bone (cortical/total area) as well as the osteoblast number relative to bone perimeter (N.Ob/BPm, mm−1) and the percentage of bone surface
covered by osteoclasts (Oc.S/BS, %) were measured. OVX: ovariectomy. Data represent mean ± SD (𝑛 = 8). ∗𝑃 < 0.05.
3.2. Effects on Vertebral Bone. Histomorphometric analysis
of vertebral bone showed a significant reduction in the ratio
cortical area/total area accompanied with a tendency to a
lower trabecular area/total area ratio in sham-operated or
ovariectomized Nrf2-deficient mice compared with wild-
type controls (Figure 2). In addition, a tendency to higher
osteoblast numbers was observed in the presence of Nrf2
deficiency in either sham-operated or ovariectomized ani-
mals. Interestingly, osteoclast surface was significantly higher
in Nrf2−/− mice relative to their corresponding wild-type
controls. Ovariectomy tended to reduce osteoblast numbers
and significantly increased osteoclast surface.
3.3. Effects on Serum Markers of Bone Turnover. No signif-
icant effects were obtained for serum ALP and osteocalcin
(early and late markers of osteoblast differentiation, resp.)
levels (Figure 3) although a tendency to higher values was
observed in the presence of Nrf2 deficiency. CTX-I and
TRAP-5b levels indicate osteoclast activity and osteoclast
number, respectively, and the ratio CTX-I/TRAP-5b is a
sensitive resorption index [24]. CTX-I/TRAP-5b as well as
the ratio RANKL/OPG, an index of osteoclastic activation,
increased in Nrf2−/− mice. In addition, ovariectomy aug-
mented CTX-I/TRAP-5b and RANKL/OPG.
3.4. Osteoclast Differentiation. Increased serum levels of
TRAP-5b/CTX-I and RANKL/OPG as well as osteoclast
surface in vertebrae sections were observed in Nrf2−/− mice.
In order to confirm the response to relevant osteoclastogenic
stimuli [16, 17] in our experimental model, we used bone
marrow-derived cells ofmice from the different experimental
groups treated withM-CSF and RANKL. Figure 4 shows that
deficiency inNrf2 enhanced in vitro osteoclast differentiation
in either sham-operated or ovariectomized animals.
3.5. Oxidative Stress. The possible effects on ROS production
were investigated in our experimental model. For this pur-
pose, we assessed oxidative stress in bone marrow-derived
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Figure 3: Serum levels of bone turnover markers. ALP was assessed by the method of Kind and King [21]. TRAP-5b and CTX-I levels were
measured by ELISA. Osteocalcin, OPG, and RANKL levels were measured by Luminex. OVX: ovariectomy. Results are expressed as mean ±
SD (𝑛 = 8). ∗𝑃 < 0.05, ∗∗𝑃 < 0.01.
cells by quantifying intracellular ROS accumulation. As
expected, Nrf2 deficiency resulted in a higher oxidative stress
either in sham-operated or ovariectomized mice (Figure 5).
In addition, ovariectomy tended to increase ROS production.
4. Discussion
A wide range of evidence indicates that Nrf2 regulates the
expression of genes involved in cellular detoxification and
maintains cellular redox homeostasis [25, 26]. In this work,
we focused on the possible role of Nrf2 in bone metabolism
because oxidative stress is an important mediator of bone
loss in estrogen deficiency. Analysis of bone parameters in
Nrf2−/− mice and their wild-type littermates either in the
absence or presence of ovariectomy showed that Nrf2 is
required for the maintenance of bone quality. We demon-
strate that mice deficient in Nrf2 exhibit a loss in trabecular
bone mineral density in femora and a reduction in cortical
bone area in vertebrae. These changes induced by Nrf2
deficiency may result in bone fragility and fracture risk.
Nevertheless, enhanced bone formation activity has been
reported in 9-week-old Nrf2−/−mice [27]. Further studies are
needed to determine the influence of age on Nrf2 regulatory
effects in bone.
This study has demonstrated an increased production of
ROS by bone marrow cells from either sham-operated or
ovariectomized Nrf2-deficient mice which is consistent with
the constitutive lower levels of antioxidants reported in cells
from these animals [9]. A wide range of evidence indicates
that ROS are intermediaries in osteoclast metabolism leading
to osteoclast differentiation or activation [7, 28]. Therefore,
ROS are mediators of RANKL signaling in osteoclasts [29]
although they do not seem to be directly involved in the
bone resorption process [30]. We have shown that Nrf2
deficiency increases osteoclast numbers in vivo which would
be the consequence of a higher osteoclastogenic stimulation.
Previous in vitro studies have shown higher levels of osteo-
clast differentiation induced by RANKL and bone resorption
using cells from Nrf2-deficient mice [17, 27]. In addition
to a higher responsiveness of bone marrow-derived cells
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Figure 4: Osteoclast differentiation of bone marrow-derived cells. Cells were cultured in complete DMEM medium containing M-CSF
(30 ng/mL) and RANKL (50 ng/mL). TRAP staining was performed after 8 days of culture and TRAP+multinucleated cells were counted. (a)
Representative images, originalmagnification×400. OVX: ovariectomy. (b) Cell quantification. Data representmean± SD (𝑛 = 4). ∗𝑃 < 0.05,
∗∗
𝑃 < 0.01.
to osteoclastogenic stimuli in vitro, we have demonstrated
the consequences of Nrf2 deficiency on relevant in vivo
biomarkers such as the ratio RANKL/OPG in serum which
was significantly increased leading to enhanced osteoclast
differentiation in vivo. Serum levels of resorption markers
and the 𝜇CT and histomorphometric analyses confirmed
that the increased osteoclast number reflects an increased
bone resorption in vivo. We have also shown a high produc-
tion of oxidative stress in bone marrow-derived cells after
ovariectomy. The accumulation of ROS in these cells would
activate T cells through CD80 upregulation on dendritic
cells [31]. In addition, the lowering of antioxidants by estro-
gen deficiency may sensitize osteoclasts to osteoclastogenic
signals promoting bone resorption [7]. Nevertheless, our
results in this experimental model suggest that the maximal
osteoclastogenic response to oxidative stress would be elicited
by Nrf2 deficiency as ovariectomy did not further increase it.
On the other hand, an increased oxidative stress may
contribute to the inhibition of osteoblast differentiation [32]
and proliferation [33] or the induction of cell death [34].
Previous studies have suggested the involvement of Nrf2 in
bone mineralization. Stable overexpression of Nrf2 inhibits
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Figure 5: Production of oxidative stress by bone marrow-derived cells. Oxidative stress was measured in bone marrow-derived cells
stimulated with TPA by flow cytometry using dihydrorhodamine 123 (DHR). RFI: relative fluorescence intensity; OVX: ovariectomy. Data
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runt-related transcription factor 2-dependent osteocalcin
promoter activity and the formation of mineralized matrix in
MC3T3-E1 cells [18]. Recent data also support a negative role
for Nrf2 in osteoblast differentiation andmineralization [27].
In contrast, the lack of Nrf2 may facilitate the negative effects
of ionizing radiation on osteoblast mineralization [15]. Our
data indicate that Nrf2 deficiency tended to increase the in
vivo levels of osteoblastic markers and significantly enhanced
osteoclastic markers in sham-operated animals. Therefore,
we have shown that Nrf2 deficiency leads to an enhanced
bone turnover and the predominance of bone resorption.
The results of our study thus support a role for Nrf2 in bone
metabolism in vivo.
Development of therapies for improving bone forma-
tion and bone repair has considerable impact. We found
that genetic deletion of Nrf2 enhances bone turnover and
results in deterioration of bone structure either in sham-
operated or ovariectomized mice. Our data indicate that
this transcription factor is indispensable for normal bone
microarchitecture and suggest that Nrf2 may be a pharmaco-
logical target tomaintain bone integrity in pathological situa-
tions.
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